| Multi-Class Combination Drugs |
 |
Atripla (efavirenz + tenofovir + emtricitabine) |
| Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs) |
 |
Combivir (zidovudine + lamivudine, AZT + 3TC) |
 |
Epzicom (Kivexa, abacavir + lamivudine, ABC + 3TC) |
 |
Trizivir (abacavir + zidovudine + lamivudine, ABC + AZT + 3TC) |
 |
Truvada (tenofovir DF + emtricitabine, TDF + FTC) |
 |
Videx & Videx EC (didanosine, ddI) |
 |
Viread (tenofovir disoproxil fumarate, TDF) |
 |
Remune (HIV-1 Immunogen, Salk vaccine |
|
|
| Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) |
| Protease Inhibitors (PIs) |
 |
Kaletra (Aluvia, lopinavir/ritonavir, LPV/r) |
 |
Lexiva (Telzir, fosamprenavir, FPV) |
| Entry Inhibitors (including Fusion Inhibitors) |
|
HIV TREATMENT
Pictured are existing medication
